Virbac has licensed novel therapeutic antibodies from MabGenesis to enhance its canine health offerings, reflecting a strategic move towards innovative veterinary solutions.

Information on the Target

Virbac, a leading global player in the animal health sector, has announced a strategic licensing agreement with MabGenesis, a biopharmaceutical company based in Yokohama, Japan. This collaboration is focused on the development and commercialization of novel therapeutic antibodies specifically designed for canine diseases. With this agreement, Virbac aims to tap into advanced biotechnological advancements that will enhance veterinary treatments and strengthen its portfolio of animal health solutions.

MabGenesis specializes in developing therapeutic monoclonal antibodies, having established innovative technologies backed by over 30 years of academic research. Their groundbreaking platform, which utilizes high-quality phage display antibody libraries, enables the rapid and efficient isolation of species-specific monoclonal antibodies. This partnership is expected to expand Virbac’s capabilities in providing effective therapeutic options for canine health.

Industry Overview in Japan

The animal health industry in Japan is witnessing steady growth, driven by increasing pet ownership and awareness of animal health and welfare. As one of the countries with a significant number of pet cats and dogs, Japan's market for vete